Best of ASCO - 2014 Annual Meeting

 

Welcome

Multiple Myeloma

Hematologic Malignancies—Plasma Cell Dyscrasia

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma.

James Chim

e19521

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Donna Ellen Reece

8025

A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).

James R. Berenson

8048

Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sara Bringhen

8043

Appendicular skeleton MRI in multiple myeloma: Utility and clinical implications.

Navid Faraji

e19527

Association between immunoglobulin isotypes and cytogenetic risk groups in multiple myeloma.

Ramya Muddasani

e19510

Biomodulatory therapy approach with lenalidomide in combination with pioglitazone, dexamethasone, and metronomic low-dose chemotherapy with treosulfan in patients with relapsed/refractory multiple myeloma > second-line.

Daniel Heudobler

8037

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).

Sonja Zweegman

TPS8056

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

Pieter Sonneveld

TPS8055

Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Osman Ilhan

e19524

Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.

Thierry Facon

8028

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma.

Claudio Cerchione

e19522

Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.

Smith Giri

8044

Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.

Bharat Nandakumar

e19519

Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.

chunrui li

8013

Clinical significance of CXCR5-CXCL13 signaling in multiple myeloma.

Olayinka omoyitola Adebayo

e19517

Concordance and discordance in myeloma bone marrow studies.

Vincent Louie Mendiola

e19508

Continued improvement in survival in multiple myeloma (MM) including high-risk patients.

Bharat Nandakumar

8039

Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM).

Chutima Kunacheewa

8024

Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma.

Josh John Carlson

e19529

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Sagar Lonial

8001

Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study.

Jason Tay

e19509

ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.

Michael A. Thompson

TPS8052

Effect of iFISH defined 1q21 amplification/gain in multiple myeloma patients treated on total therapy protocols.

Maurizio Zangari

8023

Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.

Cristina Gasparetto

8032

Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors.

Loui Madakamutil

e19512

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel

8040

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

Jonathan L. Kaufman

8038

Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Maria-Victoria Mateos

8005

Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.

Francesca Gay

8002

Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.

Herve Avet-Loiseau

8017

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.

Max S. Topp

8007

Factors associated with over and underuse of response evaluation in elderly myeloma patients.

Siyang Leng

e19518

Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.

Aurore Perrot

8016

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial

8006

Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.

Saad Zafar Usmani

8035

Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival.

Ala Abudayyeh

e19535

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity.

Marcella Tschautscher

8034

Inching towards precision medicine for multiple myeloma with causal network models.

Jun Zhu

e19526

Incidence of serious adverse events in bortezomib, lenalidomide and bortezomib plus lenalidomide maintenance for multiple myeloma: Interim analysis of MMRF-CoMMpass study.

Venkata Vosuri

e19516

Local activator and T cell engager (LocATE) selectively blocks PD-L1 at the cytolytic synapse for deeper responses in multiple myeloma.

Christian Leisner

8045

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03).

Arthur Bobin

8029

Minimal residual disease clinical monitoring and depth of response in multiple myeloma.

Joaquin Martinez-Lopez

8026

Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma.

Nathanael Fillmore

8033

Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

Philippe Moreau

e19505

Outcomes of patients with t(11;14) multiple myeloma: An international myeloma working group (IMWG) multicenter study.

Brian G. Durie

8015

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Paul G. Richardson

8014

Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.

Jeroen Elassaiss-Schaap

8022

Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

Philippe Moreau

8003

Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).

Luciano J. Costa

TPS8053

Plasma cell-free DNA chromosomal instability score as early predictor to monitor tumor burden in response to therapeutic in multiple myeloma patients.

Juan Du

8036

Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Taner Demirer

e19532

Project Switch: Lenalidomide and dexamethasone (Len-Dex) as a potential synthetic control arm (SCA) in relapsed or refractory multiple myeloma (rrMM).

Bindu Kanapuru

8047

Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).

Parameswaran Hari

8030

Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study.

Adam Justin Waxman

e19534

Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy.

Evangelos Terpos

e19515

Role of extra corporeal methods for light chain removal on renal recovery in multiple myeloma: A systematic review.

Hamza Hassan

e19530

Role of investigational monoclonal antibodies in the treatment of multiple myeloma: A systematic review.

Hamza Hassan

e19533

Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.

Maria-Victoria Mateos

8027

Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.

William Bensinger

8012

Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM).

Angela Dispenzieri

8020

SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.

Al-Ola A. Abdallah

TPS8054

Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.

Cyrille Hulin

8042

The impact of newly approved drugs on clinical and operational strategies for multiple myeloma clinical trials.

Bhavani Krishnan

e19511

The myeloma-developing regimens using genomics (MyDRUG) master protocol.

Daniel Auclair

TPS8057

The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Barry Paul

e19514

The unforeseen business and medical consequences of EHR data collection for a real-world data multiple myeloma registry.

Kevin M. Keogh

e19528

Time to first treatment is an independent prognostic factor for multiple myeloma (MM).

Gaurav Goyal

e19523

Treatment patterns and outcomes among t(11;14) myeloma patients in a real-world setting.

Andrew David Norden

e19531

Treatment patterns in patients with multiple myeloma (MM): A retrospective study using Medicare data.

Peggy L. Lin

e19506

Treatment sequencing patterns for relapsed refractory multiple myeloma (RRMM) in the era of new therapies in a single center institution.

Alexandre Tungesvik

e19513

Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.

Jesus San Miguel

8000

Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC).

Wilson I. Gonsalves

8031

Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.

Marion Eveillard

e19525

Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis.

Rajshekhar Chakraborty

e19503

Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.

Cecile Gruchet

8041